

DAFTAR PUSTAKA

1. PERKENI. Konsensus Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia 2015. PB PERKENI; 2015.
2. WHO. Global report on diabetes. 2016. 20-33.
3. Pusat Data dan Informasi Kementerian Kesehatan RI. Infodatin: Situasi dan Analisis Diabetes. 2014.
4. Katzung BG, Masters SB, Trevor AJ. Basic & Clinical Pharmacology, 12th ed. McGraw-Hill; 2012.
5. Kulczyński B, Gramza-Michałowska A. Goji Berry (*Lycium barbarum*): Composition and Health Effects - A Review. Polish J Food Nutr Sci. 2016; 67-75. doi:10.1515/pjfn-2015-0040.
6. Bucheli P, Gao Q, Redgwell R, Karine V, Wang J, Zhang W. Biomolecular and Clinical Aspects of Chinese Wolfberry. In: Herbal Medicine: Biomolecular and Clinical Aspects. 2011; doi:10.1201/b10787-15.
7. Amagase H. General Toxicity and Histological Analysis from Acute Toxicological Study of a Standardized *Lycium barbarum* (Goji) Juice (GoChiTM) in Rodents. Faseb J. 2008; 2: 722.
8. Luo Q, Wang Li J, Zhang SH. Effect of *Lycium barbarum* polysaccharides-X on reducing blood glucose in diabetic rabbits. Chin J Trophology. 1997; 173-7.
9. Li Q, Zhang GJ, Feng R, Fu XH, Mao JC, Wang Y. Clinical research of diabetic retinopathy treated with Tang-an-kang. J Chengdu Univ Trad Chin Med. 1999; 23-6.
10. SM Tan. Study on the hypoglycemic effect of wolfberry. J South Med Univ. 2008; 2103-4.
11. Zhao R, Li Q, Xiao B. Effect of *Lycium barbarum* Polysaccharide on the Improvement of Insulin Resistance in NIDDM Rats. Yakugaku Zasshi. 2005; doi:10.1248/yakushi.125.981.

12. Cai H, Liu F, Zuo P, Huang G, Song Z, Wang T et al. Practical application of antidiabetic efficacy of *Lycium barbarum* polysaccharide in patients with type 2 diabetes. *Med Chem*. 2015; 11(4): 383-90. doi:10.2174/1573406410666141110153858.
13. Wojdyło A, Nowicka P, Bąbalewski P. Phenolic and carotenoid profile of new goji cultivars and their anti-hyperglycemic, anti-aging and antioxidant properties. *J Funct Foods*. 2018; 632-42. doi:10.1016/j.jff.2018.07.061.
14. Rodwell VW, Bender DA, Botham KM, Kennelly PJ, Weil PA. *Harper's Illustrated Biochemistry*, 30th ed. McGraw-Hill; 2015.
15. Damager I, Numao S, Chen H, Brayer GD, Withers SG. Synthesis and characterisation of novel chromogenic substrates for human pancreatic α -amylase. *Carbohydr Res*. 2004; doi:10.1016/j.carres.2004.05.019.
16. Li Y, Wen S, Kota BP, Peng G, Li GQ, Yamahara J et al. *Punica granatum* flower extract, a potent α -glucosidase inhibitor, improves postprandial hyperglycemia in Zucker diabetic fatty rats. *J Ethnopharmacol*. 2005; doi:10.1016/j.jep.2005.02.030.
17. Tortora GJ, Derrickson B. *Principles of Anatomy and Physiology*, 14th ed. Hoboken: John Wiley & Sons, Inc; 2014.
18. Nelson D, Cox M. *Lehninger Principles of Biochemistry*, 6th ed. New York: W. H. Freeman and Company; 2013.
19. Yang Y, Li W, Li Y, Wang Q, Gao L, Zhao J. Dietary *Lycium barbarum* polysaccharide induces Nrf2/ARE pathway and ameliorates insulin resistance induced by high-fat via activation of PI3K/AKT signaling. *Oxid Med Cell Longev*. 2014; doi:10.1155/2014/145641.
20. Lieberman M, Marks AD, Peet A. *Mark's Basic Medical Biochemistry-A Clinical Approach*, 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2013.
21. Hall JE. *Guyton and Hall-Textbook of Medical Physiology*, 13th ed. Philadelphia: Elsevier; 2016.
22. Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, and response to therapeutic interventions. *Lancet*

Diabetes Endocrinol. 2016; 4(6): 525–36. doi:10.1016/S2213-8587(15)00482-9.

23. Cho YM, Fujita Y, Kieffer TJ. Glucagon-Like Peptide-1: Glucose Homeostasis and Beyond. *Annu Rev Physiol*. 2014; 76: 535–59. doi:10.1146/annurev-physiol-021113-170315.
24. Rehfeld JF. The Origin and Understanding of the Incretin Concept. *Front Endocrinol (Lausanne)*. 2018; 9(387): 1–7. doi:10.3389/fendo.2018.00387.
25. R. Mentlein. Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP. *Best Pract Res Clin Endocrinol Metab*. 2009; 23(4): 443–52. doi:10.1016/j.beem.2009.03.005.
26. Christensen M, Vedtofte L, Holst JJ, Vilsbøll T, Knop FK. Glucose-Dependent Insulinotropic Polypeptide: A Bifunctional Glucose-Dependent Regulator of Glucagon and Insulin Secretion in Humans. *Diabetes*. 2011; 60(12): 3103–9. doi:10.2337/db11-0979.
27. Amagase H, Farnsworth NR. A review of botanical characteristics, phytochemistry, clinical relevance in efficacy and safety of *Lycium barbarum* fruit (Goji). *Food Res Int*. 2011; 44(7): 1702–17. doi:10.1016/j.foodres.2011.03.027.
28. Padila. *Asuhan Keperawatan Penyakit Dalam*. Yogyakarta: Nuha Medika; 2013.
29. McPherson RA, Pincus MR. *Henry's Clinical Diagnosis and Management by Laboratory Methods*, 23rd ed. St. Louis, Missouri: Elsevier; 2017.
30. Madiyono B, Moeslichan M, Sastroasmoro S, Budiman I, Purwanto S. *Dasar-dasar Metodologi Penelitian Klinis*, 4th ed. Jakarta: Sagung Seto; 2011.
31. KEMENKES RI. *Pedoman Gizi Seimbang (Pedoman teknis bagi petugas dalam memberikan penyuluhan gizi seimbang)*. Jakarta: Kementerian Kesehatan RI; 2014.
32. Strasinger S, Di Lorenzo M. *The Phlebotomy Textbook*, 3rd ed. FA Davis Company; 2011.

33. Röder PV, Wu B, Liu Y, Han W. Pancreatic regulation of glucose homeostasis. *Exp Mol Med*.2016; 48. doi:10.1038/emm.2016.6.
34. NICE.Type 2 diabetes: prevention in people at high risk. 2012.

